Emerging research reveals that fat cells can deprive cancer cells of nutrients, preventing them from growing or spreading. The study, published in Nature Biotechnology, highlights the potential of adipose manipulation transplantation (AMT) as a novel therapy to substantially slow cancer progression and provide an alternative to conventional treatments.
Limitations of Current Cancer Therapies
Cancer remains one of the leading causes of death worldwide. Although radiation, chemotherapy, targeted therapies, and immunotherapies have improved survival rates, they often carry toxic side effects, face resistance from mutations, and struggle against the complexities of the tumor microenvironment (TME). The TME contains diverse cells that help tumors survive and adapt by reprogramming metabolic pathways to access essential nutrients.
Role of Brown and Beige Fat in Tumor Suppression
Previous studies demonstrated that activating brown adipose tissue (BAT)—which burns energy to keep the body warm—can significantly suppress tumor growth. By consuming glucose and fatty acids, BAT essentially starves cancer cells. Cold exposure in mice stopped cancer growth, and similar results were reported in a patient with non-Hodgkin lymphoma. However, cold therapy is not practical for many patients with fragile health.
To address this limitation, Nadav Ahituv, PhD, at the University of California San Francisco, and Hai Nguyen, PhD, at the University of Texas Austin, explored beige fat cells, which are metabolically more active than both brown and white fat. Using CRISPR technology, they activated dormant genes in white fat to generate beige cells and identified UCP1 as a key gene driving this effect.
Engineered Adipocytes Suppress Tumor Growth
When researchers transplanted these modified adipocytes into animal tumor models, they observed striking reductions in tumor growth. Increased UCP1 protein expression enabled adipocytes to consume greater amounts of glucose and fatty acids, leaving fewer nutrients for cancer cells.
“In our very first trans-well experiment, very few cancer cells survived. We thought we had messed something up—we were sure it was a mistake,” Ahituv said. “So, we repeated it multiple times, and we kept seeing the same effect.”
In mouse models of pancreatic and breast cancer, these engineered adipose organoids reduced tumor size, limited blood vessel formation, and lowered oxygen deprivation inside tumors. Similarly, when researchers co-cultured human breast cancer organoids with engineered adipocytes, cancer growth and proliferation slowed markedly.
Innovative Delivery Approaches
As reported by pharmacytimes, the team also tested different delivery methods. By administering tetracycline or embedding engineered adipocytes into scaffold-based systems near tumors, they further suppressed cancer progression. Another strategy involved modifying adipose organoids to overexpress UPP1, an enzyme that breaks down uridine. This approach starved pancreatic ductal adenocarcinoma cells, further impairing their growth.
Advantages of Adipose Manipulation Transplantation
One key advantage of AMT is the ease of harvesting fat cells from patients, engineering them in the lab, and reintroducing them into the body. These cells can be tailored to express specific genes and showed stability once transplanted. Importantly, adipocytes interact minimally with surrounding tissues, reducing the risk of unintended side effects.
“With fat cells, there’s less interaction with the environment, so there’s very little worry of the cells leaking out into the body, where they might cause problems,” Ahituv explained.
A Potentially Safer, Targeted Therapy
The findings suggest that AMT could become a powerful, customizable therapy by depriving tumors of vital nutrients. While more studies are needed before clinical application, this approach may pave the way for less toxic, more precise cancer treatments. By harnessing the body’s own metabolic processes, researchers are opening a new frontier in oncology.